U-Neuron Biomedical Inc

NT$58.20As of Sun 8 Nov 2026, 12:00 UTC

TPEx:6973—

Country Taiwan

PE (Fwd) —

TSR 3Y CAGR 2.88%

Div yield —

ROE (7.26%)

—

Beta (5Y) —

PE TTM —

TSR TTM 38.08%

Mkt cap NT$2.899B

ROIC (12.78%)

SE Grade™

—

Value

—

Quality

Moat

1Y Price

Reference

NT$61

—

5.36%

—

—

TTM

FYE 31 Dec TWD

FY2022

FY2023

FY2024

FY2025

FY2026E

Trend

5Y

10Y

Peers

82.66

RevenueNT$M

—

—

—

—

—

—

26.79

27.02

46.21

82.66

96.72

45.59%

—

—

78.89

Revenue growth%

—

—

—

—

—

—

—

0.87

71.00

78.89

17.00

71.00

—

—

67.00

Gross margin%

—

—

—

—

—

—

80.56

79.78

82.08

67.00

66.96

80.17

—

—

(78.85)

Operating margin%

—

—

—

—

—

—

(163.04)

(334.24)

(149.23)

(78.85)

(89.55)

(156.14)

—

—

(66.89)

Net margin%

—

—

—

—

—

—

(161.15)

(314.14)

(129.77)

(66.89)

(76.45)

(145.46)

—

—

—

P/E ratio (avg)x

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

EV/EBITx

—

—

—

—

—

—

—

—

—

—

—

—

—

—

(3.78)

FCF yield (avg)%

—

—

—

—

—

—

—

—

(6.29)

(5.29)

(4.28)

(5.79)

—

—

(103.53)

FCF margin%

—

—

—

—

—

—

(148.38)

(205.75)

(213.77)

(103.53)

(100.00)

(177.06)

—

—

1.548

FCF / Net incomex

—

—

—

—

—

—

0.921

0.655

1.647

1.548

—

1.234

—

—

(12.78)

ROIC%

—

—

—

—

—

—

(31.96)

(31.07)

(12.06)

(12.78)

(25.98)

(21.92)

—

—

(7.26)

Return on equity%

—

—

—

—

—

—

(26.44)

(25.91)

(9.20)

(7.26)

(10.97)

(17.56)

—

—

(7.24)

Return on assets%

—

—

—

—

—

—

(23.17)

(16.23)

(7.08)

(7.24)

(10.72)

(11.73)

—

—

(1.42)

EPSNT$

—

—

—

—

—

—

(2.70)

(3.42)

(1.76)

(1.42)

(1.90)

—

—

—

19.32

EPS growth%

—

—

—

—

—

—

—

(26.72)

48.44

19.32

(33.72)

19.32

—

—

18.30

Bookvalue per shNT$

—

—

—

—

—

—

10.21

19.82

23.86

18.30

16.39

21.48%

—

—

(2.20)

FCF per shareNT$

—

—

—

—

—

—

(2.49)

(2.24)

(2.91)

(2.20)

(2.49)

—

—

—

—

Dividend per shNT$

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

Div yield (avg)%

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

Payout ratio%

—

—

—

—

—

—

—

—

—

—

—

—

—

—

49.80

Shares (diluted)M

—

—

—

—

—

—

15.99

24.82

34.00

38.86

◌38.86

34.44%

—

—

(14.29)

Buyback yield%

—

—

—

—

—

—

—

(55.18)

(36.99)

(14.29)

◌—

(36.99)

—

—

0.022

D/E ratiox

—

—

—

—

—

—

0.027

0.020

—

0.022

0.025

0.021

—

—

2.509

Enterprise valueNT$B

—

—

—

—

—

—

—

—

1.457

1.230

1.969

(15.62%)

—

—

—

LT debtNT$M

—

—

—

—

—

—

—

—

—

—

—

—

—

—

Peers (US$47.48M)

Cap (US$)

PE

G&E Herbal Biotechnolo…

51.96M

30.98x

Synbio Tech Inc.

46.65M

10.90x

GenMont Biotech…

43.25M

20.79x

47.50M

—

Capital

TTM

5Y

10Y

Leveragex

—

—

—

EBIT/Intx

(103.6)

(332.0)

(332.0)

Own earn%

—

—

—

Sh yield%

(14.29)

(36.99)

(36.99)

Owners

Insiders/Inst%

42.50

6.95

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

0/4

Revenue growth years

3/3

EPS growth years

2/3

Dividend streakyrs

0

Op margin range%

−334–−79

$1 testx

—

Incr. ROIC%

−12

Growth vs revenue

Latest

Trend

3Y CAGR

Rel growth

Revenue

NT$82.66M

45.59%

1.00×

Cost of revenue

NT$27.27M

73.65%

1.70×

Operating expenses

NT$120.6M

22.71%

0.60×

Asset mix

Share

Trend

Cash and investments

53.04%

Other

46.96%

Reinvestment returns

No breakdown available